Top Track 250

This Bath University spin-out became a commercial operation in 2006, producing specialist, individually tailored medicines such as patient-specific chemotherapy. The company has two sister businesses: Pharmaxo, which provides traditional pharmacy and hi-tech homecare services, and Microgenetics, a biotech start-up specialising in microbiology and pathogens. Overseen by co-founder and chief executive Chris Watt, 51, the group has focused its research on increasing the shelf life of biological chemotherapy drugs, significantly reducing wastage. Sales rose 26% to £239.6m in 2019.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
CompanyQualasept Pharmaxo
ActivityPharmaceuticals manufacturer
Sales £m239.6
Operating profit £m17.4
Main shareholdersRichard Wastnage (50%), Christopher Watt (44%), Maria Watt (6%)

If applicable:

* supplied by Company   † annualised figure   ‡  profit = ebitda